Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Exploiting NRF2-ARE pathway activation in papillary renal cell carcinoma.

International journal of cancer - 1 Apr 2025

Angori Silvia, Lakshminarayanan Harini, Banaei-Esfahani Amir, Mühlbauer Katharina, Bolck Hella Anna, Kallioniemi Olli, Pietiäinen Vilja, Schraml Peter, Moch Holger

Abstract excerpt

Papillary renal cell carcinoma (pRCC) is the second most frequent renal cancer subtype but has no indicated targeted treatments. MET inhibition may be a treatment for MET-driven pRCC, but there is a large group of non-MET-driven pRCC without targeted therapy. Activation of NRF2-ARE pathway has been suggested to be involved in pRCC. To study the relevance of the NRF2-ARE pathway, we characterized 60 pRCCs by copy...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Renal Cell
Share to Exome Sequencing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Expression Regulation, Neoplastic

Share to Kelch-Like ECH-Associated Protein 1

Share to Kidney Neoplasms

Share to NAD(P)H Dehydrogenase (Quinone)

Share to NF-E2-Related Factor 2

Share to Proto-Oncogene Proteins c-met

Source

Open in PubMed Open full text

Identifiers

PMID: 39707614
DOI: 10.1002/ijc.35311
PMCID: PMC11789458

Genes

MET
NQO1
BACH1
CUL3
KEAP1
NFE2L2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Exploiting NRF2-ARE pathway activation in papillary renal cell carcinoma.PMID 39707614Read ↗

Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma.Semantic proximity Read ↗

Keap1/Nrf2 pathway in kidney cancer: frequent methylation of KEAP1 gene promoter in clear renal cell carcinomaSemantic proximity Read ↗

CUL3 and NRF2 mutations confer an NRF2 activation phenotype in a sporadic form of papillary renal cell carcinoma.Semantic proximity Read ↗

Nrf2 gene mutation and single nucleotide polymorphism rs6721961 of the Nrf2 promoter region in renal cell cancer.Semantic proximity Read ↗

Integrative Clinical and Molecular Characterization of Translocation Renal Cell CarcinomaSemantic proximity Read ↗

Recurrent chromosomal gains and heterogeneous driver mutations characterise papillary renal cancer evolution.Semantic proximity Read ↗

Reviving the promise of transcription factor Nrf2-based therapeutics for kidney diseasesSemantic proximity Read ↗

A core NRF2 gene set defined through comprehensive transcriptomic analysis predicts selective drug resistance and poor multi-cancer prognosisSemantic proximity Read ↗

The m6A demethylase FTO targets POLQ to promote ccRCC cell proliferation and genome stability maintenanceSemantic proximity Read ↗

Nrf2, the master redox switch: the Achilles' heel of ovarian cancer?Semantic proximity Read ↗

Exploiting the Ref-1-APE1 node in cancer signaling and other diseases: from bench to clinicSemantic proximity Read ↗

Down-regulated FDX1 inhibited the proliferation and migration of renal cell carcinoma cellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.